The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The combination of iberdomide, a novel cereblon E3 ligase modulator, with daratumumab and dexamethasone improved rates of minimal residual disease–negative complete response compared with daratumumab,
Offering practical advice for community physicians on managing toxicities while maintaining efficacy, Dr. Nooka explained how to modify standard schedules.
The authors, led by Nicolas Boissel, MD, PhD, of Hôpital Saint-Louis in Paris, France, analyzed 94 patients with high-risk B-ALL who received up to five cycles of blinatumomab during consolidation and maintenance therapy. A post hoc analysis compared outcomes in these patients with outcomes in 90 control patients treated without blinatumomab before QUEST activation.
Dr. Saad Usmani, chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the FDA approval of iberdomide plus dexamethasone in relapsed multiple myeloma. The FDA approval was announced in August 2026 and based on findings from the SUCCESSOR-2 trial.
In this video, Dr. Valeria Santini provides an overview of the SOHO 2026 MDS session. She covers novels agents and future research needs in the field.
“This approval is grounded in data from BRUIN CLL-313, which showed a significant delay in disease progression for pirtobrutinib compared to chemoimmunotherapy, along with safety and tolerability consistent with its established profile,” said Jennifer A. Woyach, MD.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
